Genprex, Inc. (GNPX)
NASDAQ: GNPX · Real-Time Price · USD
0.716
+0.021 (2.99%)
Jan 22, 2025, 10:54 AM EST - Market open
Genprex Employees
Genprex had 26 employees as of December 31, 2023. The number of employees decreased by 2 or -7.14% compared to the previous year.
Employees
26
Change (1Y)
-2
Growth (1Y)
-7.14%
Revenue / Employee
n/a
Profits / Employee
-$873,460
Market Cap
6.09M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
GNPX News
- 16 days ago - Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 5 weeks ago - Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer - PRNewsWire
- 2 months ago - Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer - PRNewsWire
- 2 months ago - Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting - PRNewsWire
- 2 months ago - Genprex to Participate in 2024 BIO Europe Conference - PRNewsWire
- 3 months ago - Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma - PRNewsWire
- 3 months ago - Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive - PRNewsWire
- 3 months ago - Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer - PRNewsWire